| ★ 31.10.2026 23:10 UTC | Is Vertex Pharmaceuticals (VRTX) Fully Priced Following Its Kidney Data Update? | Simply Wall St. |
| ★ 30.10.2026 15:31 UTC | 3 large-cap stocks with solid fundamentals | StockStory |
| ★ 30.10.2026 10:08 UTC | Vertex Pharmaceuticals Says UK Approves Casgevy for Children Aged 5 and Older | MT Newswires |
| ★ 28.10.2026 13:00 UTC | Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release | Zacks |
| ★ 28.10.2026 12:15 UTC | Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics | Zacks |
| ★ 28.10.2026 12:00 UTC | Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock | Zacks |
| ★ 28.10.2026 11:00 UTC | Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership | Business Wire |
| ★ 27.10.2026 19:45 UTC | Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue | Motley Fool |
| ★ 27.10.2026 13:09 UTC | BofA Names this Drugmaker a Top Pick on Promising Kidney Drug Data | Investing.com |
| ★ 27.10.2026 10:05 UTC | The Biotech Leader Who Erased Team Lanes | The Wall Street Journal |
| ★ 26.10.2026 20:50 UTC | Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why | Zacks |
| ★ 26.10.2026 13:45 UTC | The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2 | 24/7 Wall St. |
| ★ 26.10.2026 13:00 UTC | Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? | Zacks |
| ★ 26.10.2026 11:02 UTC | ETFs Are Net Sellers of Vertex Pharmaceuticals (VRTX) on Oct. 22 | GuruFocus.com |
| ★ 25.10.2026 03:19 UTC | Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept | Simply Wall St. |
| ★ 25.10.2026 02:09 UTC | What Vertex Pharmaceuticals Holders Bought Into | Simply Wall St. |
| ★ 24.10.2026 19:29 UTC | Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. | Motley Fool |
| ★ 24.10.2026 03:02 UTC | Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III | MarketBeat |
| 30.10.2026 16:51 UTC | What Just Happened To Alnylam Stock? | Trefis |
| 30.10.2026 12:32 UTC | Is 50% Crash Risk For Iovance Stock Real? | Trefis |
| 30.10.2026 11:15 UTC | Why Did Insmed Stock Jump? | Trefis |
| 30.10.2026 11:05 UTC | What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Oct. 28 | GuruFocus.com |
| 29.10.2026 11:27 UTC | Can Iovance Stock Fall 50%? | Trefis |
| 28.10.2026 14:23 UTC | Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack. | Barrons.com |
| 28.10.2026 12:01 UTC | What Would Slower New Drug Sales Do To Vertex Stock? | Trefis |
| 28.10.2026 11:05 UTC | What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Monday | GuruFocus.com |
| 28.10.2026 08:22 UTC | Has The Story Under Krystal Biotech Stock Run Out? | Trefis |
| 27.10.2026 14:15 UTC | Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? | Zacks |
| 26.10.2026 17:33 UTC | BHC Q3 Earnings Preview: Here's What You Should Know | Zacks |
| 24.10.2026 22:20 UTC | Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More | Motley Fool |